A5027389273- Regulation of Appetite and Obesity
- Diet and metabolism studies
- Adipose Tissue and Metabolism
- Pancreatic function and diabetes
- Chronic Kidney Disease and Diabetes
- Metabolism, Diabetes, and Cancer
- Biochemical Analysis and Sensing Techniques
- Monoclonal and Polyclonal Antibodies Research
- Mesenchymal stem cell research
- Stress Responses and Cortisol
- Neuroscience of respiration and sleep
- Muscle metabolism and nutrition
- Diabetes Treatment and Management
- Fibroblast Growth Factor Research
- Bariatric Surgery and Outcomes
- Adipokines, Inflammation, and Metabolic Diseases
- vaccines and immunoinformatics approaches
- Liver Disease Diagnosis and Treatment
- Metabolomics and Mass Spectrometry Studies
- Immunotherapy and Immune Responses
- Gut microbiota and health
- Diabetes Management and Research
- Diet, Metabolism, and Disease
- MicroRNA in disease regulation
- Neuroendocrine regulation and behavior
Eli Lilly (United States)
2008-2024
Indianapolis Zoo
2024
The peptide hormone ghrelin is the only known protein modified with an O-linked octanoyl side group, which occurs on its third serine residue. This modification crucial for ghrelin's physiological effects including regulation of feeding, adiposity, and insulin secretion. Despite role octanoylation in physiology ghrelin, lipid transferase that mediates this novel has remained unknown. Here we report identification characterization human GOAT, O-acyl transferase. GOAT a conserved orphan...
Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor (GLP-1R) agonist, delivered superior glycemic control weight loss compared with GLP-1R agonism in patients type 2 diabetes. However, the mechanism by which tirzepatide improves efficacy how (GIPR) contributes is not fully understood. Here, we show that an effective insulin sensitizer, improving sensitivity obese mice to greater extent than agonism. To determine whether GIPR contributes, effect of WT Glp-1r–null mice. In absence...
Abstract Context Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated lower circulating triglycerides lipoprotein markers improved of beta-cell function insulin resistance (IR), effects only partially attributable to loss. Objective Assess plasma metabolome changes mediated by tirzepatide. Design Phase 2b trial participants...
Biologics have the potential to induce an immune response when used therapeutically. A number of in vitro assays are currently preclinically predict risk immunogenicity, but validation these preclinical tools suffers from relatively small accessible immunogenic molecules and limited understanding mechanisms underlying immunogenicity biologics. Here, we present post-hoc analysis three monoclonal antibodies with high clinic. Two elicited a CD4 T cell proliferative multiple donors peripheral...
Oxytocin (OXT) has been shown to suppress appetite, induce weight loss, and improve glycemic control lipid metabolism in several species, including humans, monkeys, rodents. However, OXT's short half-life circulation lack of receptor selectivity limit its application efficacy. In this study, we report an OXT peptide analog (OXTGly) that is potent selective for the (OXTR). OXT, but not OXTGly, activated vasopressin receptors vitro acutely increased blood pressure vivo when administered IP....
Global proteomics profiling identified FGF20, TNFSF12, and ANGPT1 as protective against progression of renal function decline in those with diabetes.
Here, we present a targeted polar metabolomics protocol for the analysis of biofluids and frozen tissue biopsies using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). We describe steps sample pretreatment, liquid-liquid extraction, isolation metabolites. then detail procedures target LC-MS/MS analysis. In this protocol, focus on plasma serum samples. also provide brief instructions how to process other biological matrices as supplemental information. For complete...
In phase 2 (n=338), retatrutide (RETA), an agonist of GIP, GLP-1 and glucagon receptors, reduced body weight, fasting glucose, triglycerides (TG), LDL VLDL cholesterol in participants with obesity. To understand changes energy metabolism, lipidomic profiling was conducted. Adult obesity (BMI ≥30 kg/m2), or overweight ≥ 27 kg/m2) a weight related comorbidity, were randomized to RETA 1, 4, 8, 12 mg PBO for 48 wk. Fasting plasma collected at baseline, 24 wk, used measure acylcarnitines complex...